Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Conditions
Interventions
JNJ-79635322
Daratumumab
+2 more
Locations
14
Australia
Monash Medical Centre
Clayton, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
Wollongong Hospital
Wollongong, Australia
Carmel Medical Center
Haifa, Israel
Start Date
December 4, 2024
Primary Completion Date
November 19, 2027
Completion Date
November 23, 2028
Last Updated
April 13, 2026
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06870760
NCT06383143
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions